In vitro activity of antifolate and polymorphism in dihydrofolate reductase of Plasmodium falciparum isolates from the Kenyan coast: Emergence of parasites with Ile-164-Leu mutation

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 9, 2009, Pages 3793-3798

  Kiara, Steven M ^a   Okombo, John ^a   Masseno, Victor ^a   Mwai, Leah ^a   Ochola, Isabella ^a   Borrmann, Steffen ^a,b   Nzila, Alexis ^a,c  

^a KEMRI WELLCOME TRUST RESEARCH PROGRAMME   (Kenya)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4,6 DIAMINO 1,2 DIHYDRO 2,2 DIMETHYL 1 [3 (2,4,5 TRICHLOROPHENOXY)PROPOXY] 1,3,5 TRIAZINE; CHLORCYCLOGUANIL; DIHYDROFOLATE REDUCTASE; FOLIC ACID ANTAGONIST; METHOTREXATE; PYRIMETHAMINE; TRIMETHOPRIM; TRIMETREXATE;

ANTIBIOTIC RESISTANCE; ARTICLE; CODON; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; ENZYME POLYMORPHISM; GENE MUTATION; GENOTYPE; IC 50; IN VITRO STUDY; KENYA; MUTATIONAL ANALYSIS; NONHUMAN; PARASITE ISOLATION; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ANIMALS; ANTIMALARIALS; CHLOROGUANIDE; FOLIC ACID ANTAGONISTS; GENOTYPE; INHIBITORY CONCENTRATION 50; KENYA; METHOTREXATE; MUTATION; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PYRIMETHAMINE; TETRAHYDROFOLATE DEHYDROGENASE; TRIAZINES; TRIMETHOPRIM; TRIMETREXATE;

EID: 70349101632     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00308-09     Document Type: Article

References (59)

1. Alker, A. P., V. Mwapasa, A. Purfield, S. J. Rogerson, M. E. Molyneux, D. D. Kamwendo, E. Tadesse, E. Chaluluka, and S. R. Meshnick. 2005. Mutations associated with sulfadoxine-pyrimethamine and chlorproguanil resistance in Plasmodium falciparum isolates from Blantyre, Malawi. Antimicrob. Agents Chemother. 49:3919-3921.
2. Amin, A. A., D. Zurovac, B. B. Kangwana, J. Greenfield, D. N. Otieno, W. S. Akhwale, and R. W. Snow. 2007. The challenges of changing national malaria drug policy to artemisinin-based combinations in Kenya. Malar. J. 6:72.
3. Amsden, G. W., S. F. Kowalsky, and G. D. Morse. 1992. Trimetrexate for Pneumocystis carinii pneumonia in patients with AIDS. Ann. Pharmacother. 26:218-226.
4. Barnhart, K., C. Coutifaris, and M. Esposito. 2001. The pharmacology of methotrexate. Expert Opin. Pharmacother. 2:409-417.
5. Basco, L. K., and J. Le Bras. 1997. In vitro sensitivity of Plasmodium falciparum to anti-folinic agents (trimethoprim, pyrimethamine, cycloguanil): a study of 29 African strains. Bull. Soc. Pathol. Exot. 90:90-93. (In French.)
6. Bloland, P. B., S. C. Redd, P. Kazembe, R. Tembenu, J. J. Wirima, and C. C. Campbell. 1991. Co-trimoxazole for childhood febrile illness in malaria-endemic regions. Lancet 337:518-520.
7. Bukirwa, H., P. Garner, and J. Critchley. 2004. Chlorproguanil-dapsone for treating uncomplicated malaria. Cochrane Database Syst. Rev. 2004:CD004387.
8. Clarke, S. E., M. C. Jukes, J. K. Njagi, L. Khasakhala, B. Cundill, J. Otido, C. Crudder, B. B. Estambale, and S. Brooker. 2008. Effect of intermittent preventive treatment of malaria on health and education in schoolchildren: a cluster-randomised, double-blind, placebo-controlled trial. Lancet 372:127-138.
9. Dar, O., M. S. Khan, and I. Adagu. 2008. The potential use of methotrexate in the treatment of falciparum malaria: in vitro assays against sensitive and multidrug-resistant falciparum strains. Jpn. J. Infect. Dis. 61:210-211.
10. Daramola, O. O., P. L. Alonso, T. J. O'Dempsey, P. Twumasi, T. F. McArdle, and B. M. Greenwood. 1991. Sensitivity of Plasmodium falciparum in The Gambia to co-trimoxazole. Trans. R. Soc. Trop. Med. Hyg. 85:345-348.
11. Fanello, C. I., C. Karema, D. Ngamije, A. Uwimana, V. Ndahindwa, C. Van Overmeir, W. Van Doren, J. Curtis, and U. D'Alessandro. 2008. A randomised trial to assess the efficacy and safety of chlorproguanil/dapsone + artesunate for the treatment of uncomplicated Plasmodium falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 102:412-420.
12. Färnert, A., M. Lebbad, L. Faraja, and I. Rooth. 2008. Extensive dynamics of Plasmodium falciparum densities, stages and genotyping profiles. Malar. J. 7:241.
13. Fehintola, F. A., A. A. Adedeji, G. O. Gbotosho, C. T. Happi, S. T. Balogun, O. A. Folarin, A. O. Sijuade, and A. Sowunmi. 2008. Effects of artesunate-cotrimoxazole and amodiaquine-artesunate against asexual and sexual stages of Plasmodium falciparum malaria in Nigerian children. J. Infect. Chemother. 14:188-194.
14. Fehintola, F. A., A. A. Adedeji, E. Tambo, B. B. Fateye, T. C. Happi, and A. Sowunmi. 2004. Cotrimoxazole in the treatment of acute uncomplicated falciparum malaria in Nigerian children: a controlled clinical trial. Clin. Drug Investig. 24:149-155.
15. Fox, R. I., S. L. Morgan, H. T. Smith, B. A. Robbins, M. G. Choc, and J. E. Baggott. 2003. Combined oral cyclosporin and methotrexate therapy in patients with rheumatoid arthritis elevates methotrexate levels and reduces 7-hydroxymethotrexate levels when compared with methotrexate alone. Rheumatology (Oxford) 42:989-994.
16. Francis, D., S. L. Nsobya, A. Talisuna, A. Yeka, M. R. Kamya, R. Machekano, C. Dokomajilar, P. J. Rosenthal, and G. Dorsey. 2006. Geographic differences in antimalarial drug efficacy in Uganda are explained by differences in endemicity and not by known molecular markers of drug resistance. J. Infect. Dis. 193:978-986.
17. Godfrey, C., K. Sweeney, K. Miller, R. Hamilton, and J. Kremer. 1998. The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis. Br. J. Clin. Pharmacol. 46:369-376.
18. Gray, O. M., G. V. McDonnell, and R. B. Forbes. 2006. A systematic review of oral methotrexate for multiple sclerosis. Mult. Scler. 12:507-510.
19. Haller, D. G. 1997. Trimetrexate: experience with solid tumors. Semin. Oncol. 24:S18-71-S18-76.
20. Hamel, M. J., T. Holtz, C. Mkandala, N. Kaimila, N. Chizani, P. Bloland, J. Kublin, P. Kazembe, and R. Steketee. 2005. Efficacy of trimethoprim- sulfamethoxazole compared with sulfadoxine-pyrimethamine plus erythromycin for the treatment of uncomplicated malaria in children with integrated management of childhood illness dual classifications of malaria and pneumonia. Am. J. Trop. Med. Hyg. 73:609-615.
21. Hamel, M. J., A. Poe, P. Bloland, A. McCollum, Z. Zhou, Y. P. Shi, P. Ouma, K. Otieno, J. Vulule, A. Escalante, V. Udhayakumar, and L. Slutsker. 2008. Dihydrofolate reductase I164L mutations in Plasmodium falciparum isolates: clinical outcome of 14 Kenyan adults infected with parasites harbouring the I164L mutation. Trans. R. Soc. Trop. Med. Hyg. 102:338-345.
22. Hastings, M. D., S. J. Bates, E. A. Blackstone, S. M. Monks, T. K. Mutabingwa, and C. H. Sibley. 2002. Highly pyrimethamine-resistant alleles of dihydrofolate reductase in isolates of Plasmodium falciparum from Tanzania. Trans. R. Soc. Trop. Med. Hyg. 96:674-676.
23. Hyde, J. E. 2008. Antifolate resistance in Africa and the 164-dollar question. Trans. R. Soc. Trop. Med. Hyg. 102:301-303.
24. Iyer, J. K., W. K. Milhous, J. F. Cortese, J. G. Kublin, and C. V. Plowe. 2001. Plasmodium falciparum cross-resistance between trimethoprim and pyrimethamine. Lancet 358:1066-1067.
25. Jelinek, T., A. H. Kilian, J. Curtis, M. T. Duraisingh, G. Kabagambe, F. von Sonnenburg, and D. C. Warhurst. 1999. Plasmodium falciparum: selection of serine 108 of dihydrofolate reductase during treatment of uncomplicated malaria with co-trimoxazole in Ugandan children. Am. J. Trop. Med. Hyg. 61:125-130.
26. Juliano, J. J., P. Trottman, V. Mwapasa, and S. R. Meshnick. 2008. Detection of the dihydrofolate reductase-164L mutation in Plasmodium falciparum infections from Malawi by heteroduplex tracking assay. Am. J. Trop. Med. Hyg. 78:892-894.
27. Khalil, I., A. M. Ronn, M. Alifrangis, H. A. Gabar, G. M. Satti, and I. C. Bygbjerg. 2003. Dihydrofolate reductase and dihydropteroate synthase genotypes associated with in vitro resistance of Plasmodium falciparum to pyrimethamine, trimethoprim, sulfadoxine, and sulfamethoxazole. Am. J. Trop. Med. Hyg. 68:586-589.
28. Kielhofner, M. A. 1990. Trimethoprim-sulfamethoxazole: pharmacokinetics, clinical uses, and adverse reactions. Tex. Heart Inst. J. 17:86-93.
29. Kilian, A. H., T. Jelinek, I. Prislin, G. Kabagambe, W. Byamukama, G. Mpigika, R. Korte, and F. von Sonnenburg. 1998. Resistance in vivo of Plasmodium falciparum to co-trimoxazole in western Uganda. Trans. R. Soc. Trop. Med. Hyg. 92:197-200.
30. Libecco, J. A., and K. R. Powell. 2004. Trimethoprim/sulfamethoxazole: clinical update. Pediatr. Rev. 25:375-380.
31. Lynch, C., R. Pearce, H. Pota, J. Cox, T. A. Abeku, J. Rwakimari, I. Naidoo, J. Tibenderana, and C. Roper. 2008. Emergence of a dhfr mutation conferring high-level drug resistance in Plasmodium falciparum populations from southwest Uganda. J. Infect. Dis. 197:1598-1604.
32. Malamba, S. S., J. Mermin, A. Reingold, J. R. Lule, R. Downing, R. Ransom, A. Kigozi, B. M. Hunt, A. Hubbard, P. J. Rosenthal, and G. Dorsey. 2006. Effect of cotrimoxazole prophylaxis taken by human immunodeficiency virus (HIV)-infected persons on the selection of sulfadoxine-pyrimethamine-resistant malaria parasites among HIV-uninfected household members. Am. J. Trop. Med. Hyg. 75:375-380.
33. Marshall, J. L., and R. J. DeLap. 1994. Clinical pharmacokinetics and pharmacology of trimetrexate. Clin. Pharmacokinet. 26:190-200.
34. McCollum, A. M., A. C. Poe, M. Hamel, C. Huber, Z. Zhou, Y. P. Shi, P. Ouma, J. Vulule, P. Bloland, L. Slutsker, J. W. Barnwell, V. Udhayakumar, and A. A. Escalante. 2006. Antifolate resistance in Plasmodium falciparum: multiple origins and identification of novel dhfr alleles. J. Infect. Dis. 194: 189-197.
35. Menard, D., D. Djalle, F. Yapou, A. Manirakiza, and A. Talarmin. 2006. Frequency distribution of antimalarial drug-resistant alleles among isolates of Plasmodium falciparum in Bangui, Central African Republic. Am. J. Trop. Med. Hyg. 74:205-210.
36. Nair, S., B. Miller, M. Barends, A. Jaidee, J. Patel, M. Mayxay, P. Newton, F. Nosten, M. T. Ferdig, and T. J. Anderson. 2008. Adaptive copy number evolution in malaria parasites. PLoS Genet. 4:e1000243.
37. Nduati, E., A. Diriye, S. Ommeh, L. Mwai, S. Kiara, V. Masseno, G. Kokwaro, and A. Nzila. 2008. Effect of folate derivatives on the activity of antifolate drugs used against malaria and cancer. Parasitol. Res. 102:1227-1234.
38. Niehues, T., and P. Lankisch. 2006. Recommendations for the use of methotrexate in juvenile idiopathic arthritis. Paediatr. Drugs 8:347-356. (Pubitemid 44912719)
39. Nzila, A. 2006. The past, present and future of antifolates in the treatment of Plasmodium falciparum infection. J. Antimicrob. Chemother. 57:1043-1054.
40. Nzila, A., E. Ochong, E. Nduati, K. Gilbert, P. Winstanley, S. Ward, and K. Marsh. 2005. Why has the dihydrofolate reductase 164 mutation not consistently been found in Africa yet? Trans. R. Soc. Trop. Med. Hyg. 99:341-346.
41. Nzila, A. M., E. K. Mberu, J. Sulo, H. Dayo, P. A. Winstanley, C. H. Sibley, and W. M. Watkins. 2000. Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites. Antimicrob. Agents Chemother. 44:991-996.
42. Ochong, E., D. J. Bell, D. J. Johnson, U. D'Alessandro, M. Mulenga, S. Muangnoicharoen, J. P. Van Geertruyden, P. A. Winstanley, P. G. Bray, S. A. Ward, and A. Owen. 2008. Plasmodium falciparum strains harboring dihydrofolate reductase with the I164L mutation are absent in Malawi and Zambia even under antifolate drug pressure. Antimicrob. Agents Chemother. 52:3883-3888.
43. Ochong, E., A. Nzila, S. Kimani, G. Kokwaro, T. Mutabingwa, W. Watkins, and K. Marsh. 2003. Molecular monitoring of the Leu-164 mutation of dihydrofolate reductase in a highly sulfadoxine/pyrimethamine-resistant area in Africa. Malar. J. 2:46. (Pubitemid 38809235)
44. Omar, S. A., A. Bakari, A. Owiti, I. S. Adagu, and D. C. Warhurst. 2001. Co-trimoxazole compared with sulfadoxine-pyrimethamine in the treatment of uncomplicated malaria in Kenyan children. Trans. R. Soc. Trop. Med. Hyg. 95:657-660.
45. Parola, P., B. Pradines, F. Simon, M. P. Carlotti, P. Minodier, M. P. Ranjeva, S. Badiaga, L. Bertaux, J. Delmont, M. Morillon, R. Silai, P. Brouqui, and D. Parzy. 2007. Antimalarial drug susceptibility and point mutations associated with drug resistance in 248 Plasmodium falciparum isolates imported from Comoros to Marseille, France in 2004-2006. Am. J. Trop. Med. Hyg. 77:431-437.
46. Sasi, P., A. Abdulrahaman, L. Mwai, S. Muriithi, J. Straimer, E. Schieck, A. Rippert, M. Bashraheil, A. Salim, J. Peshu, K. Awuondo, B. Lowe, M. Pirmohamed, P. Winstanley, S. Ward, A. Nzila, and S. Borrmann. 2009. In vivo and in vitro efficacy of amodiaquine against Plasmodium falciparum in an area of continued use of 4-aminoquinolines in East Africa. J. Infect. Dis. 199:1575-1582.
47. Sheehy, T. W., and H. Dempsey. 1970. Methotrexate therapy for Plasmodium vivax malaria. JAMA 214:109-114.
48. Shretta, R., J. Omumbo, B. Rapuoda, and R. W. Snow. 2000. Using evidence to change antimalarial drug policy in Kenya. Trop. Med. Int. Health 5:755-764.
49. Sixsmith, D. G., W. M. Watkins, J. D. Chulay, and H. C. Spencer. 1984. In vitro antimalarial activity of tetrahydrofolate dehydrogenase inhibitors. Am. J. Trop. Med. Hyg. 33:772-776.
50. Sowunmi, A., B. A. Fateye, A. A. Adedeji, F. A. Fehintola, A. E. Bamgboye, C. P. Babalola, T. C. Happi, and G. O. Gbotosho. 2005. Effects of antifolates- co-trimoxazole and pyrimethamine-sulfadoxine - on gametocytes in children with acute, symptomatic, uncomplicated Plasmodium falciparum malaria. Mem. Inst. Oswaldo Cruz 100:451-455. (Pubitemid 41190701)
51. Staedke, S. G., H. Sendagire, S. Lamola, M. R. Kamya, G. Dorsey, and P. J. Rosenthal. 2004. Relationship between age, molecular markers, and response to sulphadoxine-pyrimethamine treatment in Kampala, Uganda. Trop. Med. Int. Health 9:624-629.
52. Temperley, M., D. H. Mueller, J. K. Njagi, W. Akhwale, S. E. Clarke, M. C. Jukes, B. B. Estambale, and S. Brooker. 2008. Costs and cost-effectiveness of delivering intermittent preventive treatment through schools in western Kenya. Malar. J. 7:196.
53. Thera, M. A., P. S. Sehdev, D. Coulibaly, K. Traore, M. N. Garba, Y. Cissoko, A. Kone, A. Guindo, A. Dicko, A. H. Beavogui, A. A. Djimde, K. E. Lyke, D. A. Diallo, O. K. Doumbo, and C. V. Plowe. 2005. Impact of trimethoprim-sulfamethoxazole prophylaxis on falciparum malaria infection and disease. J. Infect. Dis. 192:1823-1829.
54. Watkins, W. M., E. K. Mberu, P. A. Winstanley, and C. V. Plowe. 1997. The efficacy of antifolate antimalarial combinations in Africa: a predictive model based on pharmacodynamic and pharmacokinetic analyses. Parasitol. Today 13:459-464. (Pubitemid 127752379)
55. White, N. J. 2005. Intermittent presumptive treatment for malaria. PLoS Med. 2:e3.
56. Wichmann, O., T. Jelinek, G. Peyerl-Hoffmann, N. Muhlberger, M. P. Grobusch, J. Gascon, A. Matteelli, C. Hatz, H. Laferl, M. Schulze, G. Burchard, S. da Cunha, J. Beran, P. McWhinney, H. Kollaritsch, P. Kern, J. Cuadros, M. Alifrangis, and I. Gjorup. 2003. Molecular surveillance of the antifolateresistant mutation I164L in imported African isolates of Plasmodium falciparum in Europe: sentinel data from TropNetEurop. Malar. J. 2:17.
57. Wilairatana, P., D. E. Kyle, S. Looareesuwan, K. Chinwongprom, S. Amradee, N. J. White, and W. M. Watkins. 1997. Poor efficacy of antimalarial biguanide-dapsone combinations in the treatment of acute, uncomplicated, falciparum malaria in Thailand. Ann. Trop. Med. Parasitol. 91:125-132.
58. Wildbolz, A. 1973. Methotrexate in the therapy of malaria. Ther. Umsch. 30:218-222.
59. Zachariah, R., and M. Massaquoi. 2006. Cotrimoxazole prophylaxis for HIV-positive TB patients in developing countries. Trop. Doct. 36:79-82.